Online inquiry

IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9085MR)

This product GTTS-WQ9085MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&PMEL gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000733.4; NM_001200053.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 6490
UniProt ID P07766; P40967
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9085MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13523MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ4250MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ8100MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ8080MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ6912MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ6702MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ10466MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ6518MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CX-191
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW